FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286959869> ?p ?o ?g. }

• W4286959869 endingPage "1364" @default.
• W4286959869 startingPage "1355" @default.
• W4286959869 abstract "Sorafenib combined with transcatheter arterial chemoembolization (TACE) is one of the common methods in the clinical treatment of advanced hepatocellular carcinoma (HCC), but its efficacy and safety are still controversial. Therefore, we used meta-analysis to evaluate the efficacy and safety of sorafenib combined with TACE in the treatment of advanced HCC.Up to March 14, 2021, the databases of PubMed, EMBASE, Cochrane Library, CNKI and Wanfang were searched, and the randomized controlled clinical trials (RCTs) of sorafenib combined with TACE in the treatment of primary HCC were included. Two researchers independently screened the literature, extracted data and evaluated the quality according to the inclusion and exclusion criteria. Revman5.4 software was used for meta-analysis.A total of 3076 patients were included in 23 studies, including sorafenib combined with TACE group (n=1542) and TACE group (n=1534). The results of meta-analysis showed that sorafenib combined with TACE could increase the objective response rate (ORR) (RR=1.35, 95%CI: 1.24-1.48, p<0.00001), disease control rate (DCR) (RR=1.19, 95%CI: 1.11-1.28, p<0.00001), prolong the time of disease progression (TTP) (HR=0.80, 95%CI: 0.70-0.92, p=0.001), reduce the expression level of alpha-fetoprotein (AFP) (SMD=2.01, 95%CI: 1.27-2.75, p<0.00001) and vascular endothelial growth factor (VEGF) (SMD=2.62, 95% CI: 1.35-3.90, p<0.0001) in serum. However, the overall survival (OS) was not prolonged (HR=0.86, 95%CI: 0.73-1.02, p=0.09). The incidences of fatigue, diarrhea, elevated bilirubin, skin reaction of hands and feet, rash, hypertension and oral mucosal inflammation in sorafenib combined with TACE group were higher than those in TACE group (p<0.05).Sorafenib combined with TACE has some clinical benefits compared with TACE alone, but it does not seem to prolong the OS of patients with HCC, and the incidence of adverse reactions is higher, so more high-quality RCTs are needed to further study the efficacy of the combination regimen." @default.
• W4286959869 created "2022-07-25" @default.
• W4286959869 creator A5009733199 @default.
• W4286959869 creator A5016082098 @default.
• W4286959869 creator A5018403254 @default.
• W4286959869 creator A5044742970 @default.
• W4286959869 date "2021-09-27" @default.
• W4286959869 modified "2023-10-18" @default.
• W4286959869 title "Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis." @default.
• W4286959869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34564992" @default.
• W4286959869 hasPublicationYear "2021" @default.
• W4286959869 type Work @default.
• W4286959869 citedByCount "5" @default.
• W4286959869 countsByYear W42869598692022 @default.
• W4286959869 countsByYear W42869598692023 @default.
• W4286959869 crossrefType "journal-article" @default.
• W4286959869 hasAuthorship W4286959869A5009733199 @default.
• W4286959869 hasAuthorship W4286959869A5016082098 @default.
• W4286959869 hasAuthorship W4286959869A5018403254 @default.
• W4286959869 hasAuthorship W4286959869A5044742970 @default.
• W4286959869 hasConcept C126322002 @default.
• W4286959869 hasConcept C142724271 @default.
• W4286959869 hasConcept C143998085 @default.
• W4286959869 hasConcept C168563851 @default.
• W4286959869 hasConcept C204787440 @default.
• W4286959869 hasConcept C2776478404 @default.
• W4286959869 hasConcept C2777596629 @default.
• W4286959869 hasConcept C2778019345 @default.
• W4286959869 hasConcept C2778455285 @default.
• W4286959869 hasConcept C2778695046 @default.
• W4286959869 hasConcept C71924100 @default.
• W4286959869 hasConcept C90924648 @default.
• W4286959869 hasConcept C95190672 @default.
• W4286959869 hasConceptScore W4286959869C126322002 @default.
• W4286959869 hasConceptScore W4286959869C142724271 @default.
• W4286959869 hasConceptScore W4286959869C143998085 @default.
• W4286959869 hasConceptScore W4286959869C168563851 @default.
• W4286959869 hasConceptScore W4286959869C204787440 @default.
• W4286959869 hasConceptScore W4286959869C2776478404 @default.
• W4286959869 hasConceptScore W4286959869C2777596629 @default.
• W4286959869 hasConceptScore W4286959869C2778019345 @default.
• W4286959869 hasConceptScore W4286959869C2778455285 @default.
• W4286959869 hasConceptScore W4286959869C2778695046 @default.
• W4286959869 hasConceptScore W4286959869C71924100 @default.
• W4286959869 hasConceptScore W4286959869C90924648 @default.
• W4286959869 hasConceptScore W4286959869C95190672 @default.
• W4286959869 hasIssue "4" @default.
• W4286959869 hasLocation W42869598691 @default.
• W4286959869 hasOpenAccess W4286959869 @default.
• W4286959869 hasPrimaryLocation W42869598691 @default.
• W4286959869 hasRelatedWork W10794003 @default.
• W4286959869 hasRelatedWork W11388833 @default.
• W4286959869 hasRelatedWork W13454653 @default.
• W4286959869 hasRelatedWork W14450087 @default.
• W4286959869 hasRelatedWork W17199785 @default.
• W4286959869 hasRelatedWork W18264973 @default.
• W4286959869 hasRelatedWork W5959671 @default.
• W4286959869 hasRelatedWork W7808089 @default.
• W4286959869 hasRelatedWork W9288866 @default.
• W4286959869 hasRelatedWork W12611928 @default.
• W4286959869 hasVolume "26" @default.
• W4286959869 isParatext "false" @default.
• W4286959869 isRetracted "false" @default.
• W4286959869 workType "article" @default.